Isotype
Whole Chimeric Antibody
Description
CDC-enhanced Infliximab is a Fc-modified anti-TNF therapeutic biobetter. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Infliximab, the Fc region of Infliximab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Ankylosing Spondylitis (AS)
Crohn's Disease (CD)
Psoriasis Vulgaris (Plaque Psoriasis)
Psoriatic Arthritis
Rheumatoid Arthritis
Ulcerative Colitis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Infliximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
tumor necrosis factor
Background
This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine.
Alternative Names
DIF; TNFA; TNFSF2; TNLG1F; TNF-alpha
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Chimeric IgG1
Description
Infliximab is a chimeric monoclonal IgG1 antibody that specifically targets tumor necrosis factor (TNF-α or TNF-α). Infliximab was first approved by the FDA in 1998 for the treatment of various inflammatory diseases, such as chronic Crohn's disease in adults or children, ulcerative colitis in adults or children, rheumatoid arthritis and methotrexate , Ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
Indication
Ankylosing Spondylitis (AS)
Crohn's Disease (CD)
Psoriasis Vulgaris (Plaque Psoriasis)
Psoriatic Arthritis
Rheumatoid Arthritis
Ulcerative Colitis
Synonyms
infliximab-axxq, infliximab-qbtx, infliximab-abda, infliximab-dyyb
